30129-57-8

Basic information

• Product Name: 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,5-dihydro-6-methyl- (9CI)
• Synonyms: 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,5-dihydro-6-methyl- (9CI);Nsc76237;6-Methyl-1H-pyrazolo[3,4-d]pyrimidin-4(7H)-one;6-Methyl-1H-pyrazolo[3;6-METHYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4(5H)-ONE
• CAS NO: 30129-57-8
• Molecular Formula: C₆H₆N₄O
• Molecular Weight: 150.13804
• Product Categories: PYRIMIDINE
• Mol File: 30129-57-8.mol
• Article Data: 8

Chemical Properties

• Melting Point: 264-265 °C
• Boiling Point: 287.7°Cat760mmHg
• Flash Point: 127.8°C
• Appearance: /
• Density: 1.72g/cm³
• Vapor Pressure: 0.00245mmHg at 25°C
• Refractive Index: 1.819
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 9.17±0.20(Predicted)
• CAS DataBase Reference: 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,5-dihydro-6-methyl- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,5-dihydro-6-methyl- (9CI)(30129-57-8)
• EPA Substance Registry System: 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,5-dihydro-6-methyl- (9CI)(30129-57-8)

Safety Data

• Hazardous Substances Data: 30129-57-8(Hazardous Substances Data)

Usage

General Description

4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,5-dihydro-6-methyl- (9CI) is a chemical compound that belongs to the class of pyrazolopyrimidinone derivatives. It is a heterocyclic compound with a pyrazole and pyrimidine ring fused together, and it contains a methyl group at the 6th position. 4H-Pyrazolo[3,4-d]pyrimidin-4-one, 1,5-dihydro-6-methyl- (9CI) may have potential pharmaceutical applications due to its structural properties and biological activities. However, further research is needed to fully understand its medicinal properties and potential uses in the pharmaceutical industry.

InChI:InChI=1/C6H6N4O/c1-3-8-5-4(2-7-10-5)6(11)9-3/h2H,1H3,(H2,7,8,9,10,11)

Upstream product

• 117868-30-1 N-(4-cyano-1⁽²⁾H-pyrazol-3-yl)-acetamide 
• 64-19-7 acetic acid 
• 5334-31-6 5-amino-1H-pyrazole-4-carboxylic acid amide 
• 1260243-04-6 ethyl 5-amino-1H-pyrazole-4-carboxylate 
• 75-05-8 acetonitrile 
• 7722-84-1 dihydrogen peroxide 
• 16617-46-2 3-amino-4-cyano-2H-pyrazole 
• 117868-30-1 C₆H₆N₄O 
• 16617-46-2 3-Amino-4-cyanopyrazole 
• 1393709-20-0 5-(methyl(ethoxy)methylene)-aminopyrazole-4-carboxamide 

Downstream Products

• 30129-53-4 4-chloro-6-methylpyrazolo<3,4-d>pyrimidine 
• 1426309-44-5 2-[1-(2-fluorobenzyl)-6-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-4-iodo-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one 
• 1426309-45-6 2-[1-(2-fluorobenzyl)-6-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-4-hydroxy-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one 
• 1426309-43-4 4-amino-2-[1-(2-fluorobenzyl)-6-methyl-1H-pyrazolo[3,4-d]pyrimidin-3-yl]-5,5-dimethyl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one 
• 1426309-42-3 1-(2-fluorobenzyl)-6-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-carboximidamide 
• 1426309-41-2 1-(2-fluorobenzyl)-6-methyl-1H-pyrazolo[3,4-d]pyrimidine-3-carbonitrile 
• 1426309-40-1 1-(2-fluorobenzyl)-3-iodo-6-methyl-1H-pyrazolo[3,4-d]pyrimidine 
• 1415559-47-5 3-iodo-6-methyl-1H-pyrazolo[3,4-d]pyrimidine 
• 1276056-73-5 6-methyl-1H-pyrazolo[3,4-d]pyrimidine 
• 5326-80-7 6-methyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine 
• 15986-11-5 6-methyl-1,5-dihydro-pyrazolo[3,4-d]pyrimidine-4-thione 
• 144750-88-9 Dimethyl N-<4-<2-(2-methyl-4(3H)-oxo-7H-pyrazolo<3,4-d>pyrimidin-5-yl)ethynyl>benzoyl>-L-glutamate 
• 144750-91-4 Dimethyl N-<4-<2-(2-methyl-4(3H)-oxo-7H-pyrazolo<3,4-d>pyrimidin-5-yl)ethyl>benzoyl>-L-glutamate 
• 144750-94-7 N-<4-<2-(2-Methyl-4(3H)-oxo-7H-pyrazolo<3,4-d>pyrimidin-5-yl)ethyl>benzoyl>-L-glutamic acid 

Relevant articles and documents

-

-

SUBSTITUTED PYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS

A chemical entity of Formula (I), wherein V, W, Y, and Z, have any of the values described herein, and compositions comprising such chemical entities, methods of making them; and their use in a wide range of methods, including metabolic and reaction kinetic studies; detection and imaging techniques, radioactive treatments; modulating and treating disorders mediated by PDE2 activity; treating neurological disorders, CNS disorders, dementia, cognitive disorders, neurodegenerative diseases, and trauma-dependent losses of function, enhancing the efficiency of cognitive and motor training, including in stroke or TBI rehabilitation; and treating peripheral disorders, including hematological, cardiovascular, gastroenterological, dermatoiogical, inflammatory, and pain disorders.

Bioisosteric transformations and permutations in the triazolopyrimidine scaffold to identify the minimum pharmacophore required for inhibitory activity against plasmodium falciparum dihydroorotate dehydrogenase

Plasmodium falciparum causes approximately 1 million deaths annually. However, increasing resistance imposes a continuous threat to existing drug therapies. We previously reported a number of potent and selective triazolopyrimidine-based inhibitors of P.

KINASE MODULATORS AND METHODS OF USE

The present invention relates to compounds of the Formula I and II wherein R, R21, R25-R33, m, n, X21-X23, and Q1 are defined herein. The compounds modulate protein kinase enzymatic activity to modulate cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly p70S6 and/or Akt kinases. Methods of using and preparing the compounds, and pharmaceutical compositions thereof, to treat kinase-dependent diseases and conditions are also an aspect of the invention.